Abstract:A novel approach is developed for synergistic chemoimmunotherapy by utilizing dual‐responsive covalent organic frameworks (COFs) to co‐deliver doxorubicin (DOX) and programmed cell death ligand‐1 (PD‐L1) siRNA (siPD‐L1), which triggers immunogenic cell death (ICD) and suppresses PD‐L1 expression in tumor cells, thereby resulting in synergistically improved antitumor efficacy and antimetastatic effect. Chemoimmunotherapy, which integrates chemotherapeutic drugs with immune modulators, has emerged as a promising approach to enhance the generally lackluster clinical outcomes of immunotherapy. Nevertheless, a significant challenge lies in orchestrating multiple events associated with diverse mechanisms that activate antitumor immune responses. Here, a novel approach utilizing dual‐responsive covalent organic frameworks (COFs) co‐encapsulating doxorubicin (DOX) and programmed cell death ligand‐1 (PD‐L1) siRNA (siPD‐L1), termed RDAP, is presented for synergistic chemoimmunotherapy. In this system, COFs modified with poly‐L‐lysine (PLL) can adsorb DOX within their porous structure and bind siPD‐L1 onto their surface via electrostatic interactions. The resulting RDAP formulation can escape from lysosome via the "proton sponge effect" and undergo rupture upon exposure to azoreductase, leading to the efficient release of DOX and siPD‐L1 into the cytoplasm of 4T1 cells. The RDAP, harboring dual therapeutic agents, can effectively eliminate tumor cells and trigger significant immunogenic cell death (ICD) through DOX. Additionally, it concomitantly suppresses PD‐L1 expression in tumor cells, thereby significantly enhancing the antitumor immune response and resulting in synergistically improved antitumor efficacy. In mouse models, RDAP demonstrated exceptional efficacy in eliminating both primary and distant tumors, along with a pronounced antimetastatic effect against 4T1 murine breast‐to‐lung metastasis.

Tandem Chemoimmunotherapy by a Cascade-Responsive Molecular Prodrug

Bimetallic Peroxide-Based Nanotherapeutics for Immunometabolic Intervention and Induction of Immunogenic Cell Death to Augment Cancer Immunotherapy

Supramolecular Prodrug Nanovectors for Active Tumor Targeting and Combination Immunotherapy of Colorectal Cancer

Programing Immunogenic Cell Death in Breast Tumors with Designer DNA Frameworks

Dual-responsive Nanosystem Based on TGF-β Blockade and Immunogenic Chemotherapy for Effective Chemoimmunotherapy.

Stepwise Targeting and Tandem Responsive Peptide Nanoparticles Enhance Immunotherapy through Prolonged Drug Retention

Overcoming immune resistance by sequential prodrug nanovesicles for promoting chemoimmunotherapy of cancer

Tumor Microenvironment-Activatable Prodrug Vesicles for Nanoenabled Cancer Chemoimmunotherapy Combining Immunogenic Cell Death Induction and CD47 Blockade.

A Synergistic Chemoimmunotherapy System Leveraging PD-L1 Blocking and Bioorthogonal Prodrug Activation

Programmable Prodrug Micelle with Size-Shrinkage and Charge-Reversal for Chemotherapy-Improved IDO Immunotherapy.

A Dual-Responsive Doxorubicin–indoximod Conjugate for Programmed Chemoimmunotherapy

A Combinational Chemo-Immune Therapy Using an Enzyme-Sensitive Nanoplatform for Dual-Drug Delivery to Specific Sites by Cascade Targeting

Crizotinib prodrug micelles co-delivered doxorubicin for synergistic immunogenic cell death induction on breast cancer chemo-immunotherapy

Bioresponsive immune-booster-based prodrug nanogel for cancer immunotherapy

Sequential Treatment of Bioresponsive Nanoparticles Elicits Antiangiogenesis and Apoptosis and Synergizes with a CD40 Agonist for Antitumor Immunity

Plasmon‐Driven Catalytic Chemotherapy Augments Cancer Immunotherapy through Induction of Immunogenic Cell Death and Blockage of IDO Pathway

Bispecific prodrug nanoparticles circumventing multiple immune resistance mechanisms for promoting cancer immunotherapy

Prodrug-Based Versatile Nanomedicine for Enhancing Cancer Immunotherapy by Increasing Immunogenic Cell Death.

A self-cascaded unimolecular prodrug for pH-responsive chemotherapy and tumor-detained photodynamic-immunotherapy of triple-negative breast cancer

Copackaging Doxorubicin and PD‐L1 siRNA in Dual‐Responsive Covalent Organic Frameworks for Synergistic Cancer Chemoimmunotherapy

Binary Cooperative Prodrug Nanoparticles Improve Immunotherapy by Synergistically Modulating Immune Tumor Microenvironment